The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Things are going from bad to worse for the pharmaceutical giant.

Pfizer Inc. PFE on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

Pfizer is drawing healthcare attention as its obesity, oncology, vaccine, and medicine programs shape a broader pipeline ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene ...

July 8 (Reuters) - Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study ...

An experimental Pfizer hemophilia drug that takes a new approach to treating the blood clotting disorder has met the main goal of a pivotal study, setting the stage for regulatory submissions planned ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational ...